Irritable Bowel Syndrome: Understanding and Managing with Bioregulators

Irritable bowel syndrome (IBS) is a digestive disorder affecting millions, causing discomfort and disrupting daily life. Its prevalence has risen significantly, with a notable surge post-COVID-19. As more are afflicted, it underscores the need for new and effective management strategies. Alongside traditional treatments like the low-FODMAP diet, emerging research on bioregulators offers promising support for gut health.

What is IBS?

Irritable bowel syndrome is a functional gastrointestinal disorder characterized by recurrent abdominal pain, bloating, and changes in bowel habits, such as diarrhea, constipation, or both, without structural damage to the intestines. Affecting approximately 10-15% of the global population, IBS is influenced by the gut-brain axis, where stress and neuroendocrine peptides play significant roles.^[1] It’s a chronic condition that varies in severity, often requiring tailored management to improve quality of life.

Historical Trends in IBS Diagnosis

IBS diagnoses have evolved over decades, with global pooled prevalence showing fluctuations and an overall upward trend influenced by diagnostic criteria changes, increased awareness, and recent events like the COVID-19 pandemic. A comprehensive meta-analysis of studies from 1990 to 2022 reveals:

• 1990-2000: 14.18% (95% CI: 10.23%-18.66%)
• 2001-2010: 11.38% (95% CI: 8.74%-14.32%) – a slight dip possibly due to stricter criteria like Rome II
• 2011-2022: 16.52% (95% CI: 14.59%-18.55%), with a post-2020 surge linked to viral infections and stress^[1]

In the U.S. specifically, prevalence rose from 6.1% in May 2020 to 11.0% by May 2022, reflecting broader global patterns.^[2] These trends highlight the growing burden of IBS and the need for innovative management strategies.

The chart below, adapted from meta-analysis data, illustrates the global IBS prevalence trend from the 1990s to 2022:

Causes and Risk Factors

IBS arises from a complex interplay of factors. Key contributors include:

• Gut-Brain Axis Dysfunction: Stress and anxiety can disrupt gut motility and sensation.^[3]
• Post-Infectious IBS: Gastrointestinal infections, including post-COVID effects, increase risk.^[4]
• Microbiome Imbalances: Altered gut bacteria influence symptoms.
• Food Sensitivities: Certain foods, particularly those high in FODMAPs, exacerbate symptoms.
• Genetic Predispositions: Family history raises susceptibility.

Recent research highlights glucagon-like peptide-1’s (GLP-1) role in IBS pathophysiology, suggesting peptide-based therapies as a potential avenue.^[5]

Common Symptoms

IBS symptoms vary but typically include:

• Abdominal pain or cramping, often relieved by bowel movements
• Bloating and gas
• Diarrhea, constipation, or alternating patterns
• Mucus in stool

Symptoms often flare with stress, diet, or hormonal changes, making personalized management essential.

Traditional Treatments and the Low-FODMAP Diet

Today, IBS management focuses on symptom relief, with some (but limited) success to the restoration of a healthy microbiome / brain axis.

• Low-FODMAP Diet: Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols (carbohydrates that are poorly absorbed in the gut, leading to fermentation by gut bacteria) can cause bloating, gas, and pain in IBS patients. A low-FODMAP diet, developed by Monash University, restricts these foods (e.g., wheat, dairy, certain fruits, and vegetables) to reduce symptoms. Studies show it benefits up to 70% of IBS patients.^[6]
• Probiotics: To balance gut microbiota and improve digestion.
• Psychological Therapies: Cognitive behavioral therapy to manage stress-related IBS flares.
• Medications: Antispasmodics, laxatives, or antidiarrheals to address specific symptoms.

While effective, these treatments may not address underlying regulatory mechanisms, prompting exploration of bioregulators.

Bioregulators and Short Peptides for IBS

Bioregulators are gaining attention for their potential to modulate gut function. Recent studies highlight their role in IBS management:

• Stomach Bioregulator (Stamakort or Peptide Complex A-10): Research suggests peptides enhance mucosal integrity and nutrient absorption, potentially alleviating IBS-related bloating.^[7]
• Pancreas Bioregulator (Suprefort or Peptide Complex A-1): Studies indicate that pancreatic enzyme supplementation may support digestion and reduce IBS symptoms like diarrhea in patients with exocrine pancreatic insufficiency.^[8]
• Short Peptides: A recent study showed milk-derived dipeptides suppress mast cell activation, reducing IBS symptoms like pain and inflammation.^[9]
• Peptide Transporters: Di/tripeptide transporters like PepT1 modulate immune responses in the gut, which could benefit IBS patients.^[10]

These therapies are experimental but show promise in preclinical trials, with no significant adverse effects reported when used under medical supervision. Always consult a healthcare provider before trying new supplements.

Promethean Bioregulators for Gut Health

At Promethean Bioregulators, our Digestive Kickstart Bundle includes Stomach, Pancreas, Thyroid and Blood Vessel Bioregulators. Designed specifically to support gut mucosal health and nutrient absorption, this stack may help manage IBS symptoms like bloating and irregular bowel habits. It’s a great, complementary approach to traditional treatments like the low-FODMAP diet and can also be used in coordination with probiotics. While no adverse effects have been noted, always consult with your health provider when combining with prescription medicine.

Recommended Dosage and Usage

For an initial cycle, take each bioregulator in the Digestive Kickstart Bundle (four all together), twice (2x) daily, once in the morning and once in the evening, preferably with food for better absorption. Take for 30 days and monitor bloating, stomach pain and bowel movements.

If feeling better, continue with the Digestive Maintenance Plan, taking each bioregulator daily for 20 days, then cycle off for a month. If symptoms completely subside, continue with “on maintenance” every two months.

Conclusion

IBS prevalence has shown a clear upward trajectory for the last forty years, with a sharp rise post COVID-19. Environmental factors, poor nutritional choices, viruses and mental health have increased the challenges of managing IBS. The low-FODMAP diet, alongside bioregulators, offer a promising frontier for supporting gut health. While not a cure, these approaches may complement conventional treatments, helping you regain control over your digestive wellness.